PhaseBio Pharmaceuticals Inc. (PHAS) Reports Publication of Full Results from Phase 1 Clinical Trial of PB2452
PhaseBio Pharmaceuticals Inc. (PHAS) Reports Publication of Full Results from Phase 1 Clinical Trial of PB2452
Duke Signed a License Agreement with Splendo Health
Duke University and Splendo Health have entered into a license agreement. The Dutch digital health startup is a collaboration between Duke University and Splendo Consulting. Splendo Health has developed SplendoFit, a comprehensive digital platform with…